At AAOS 2016, Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain following an inadequate response to conservative non-pharmacologic therapy or analgesics.
Bioventus recently gained multi-year exclusive U.S. distribution rights for GELSYN-3™, a 3-injection hyaluronic acid product.
At AAOS 2016, Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain following an inadequate response to conservative non-pharmacologic therapy or analgesics.
At AAOS 2016, Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain following an inadequate response to conservative non-pharmacologic therapy or analgesics.
Copy to clipboard 
